gamma-aminobutyric acid type A receptor subunit beta2Genealiases: DEE92 · ICEE2
Q-omics provides the consensus-scored GABRB2 profile across patient tissues and cancer cell-line models. GABRB2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, GABRB2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, GABRB2 RNA expression shows 17,468 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, THCA, and GBM as cancer lineages where GABRB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABRB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABRB2 survival associations across molecular data types. GABRB2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABRB2 RNA expression–survival associations across cancer types. High GABRB2 expression shows unfavorable associations in COAD and UCEC, but favorable associations in HNSC, PAAD, KIRC and LGG. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for GABRB2 RNA expression.
This table summarizes GABRB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GABRB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABRB2 shows lower tumor expression in KIRC, KICH, LUSC and KIRP and higher tumor expression in THCA and LIHC. The THCA box plot shows higher GABRB2 RNA expression in tumor versus normal tissue (log2 FC = +4.965, t-test p < 0.001).
This table shows molecular features associated with GABRB2 in patient tissues and cancer cell lines. In patient samples, GABRB2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GABRB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
